| pubmed-article:16923518 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16923518 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:16923518 | lifeskim:mentions | umls-concept:C0034155 | lld:lifeskim |
| pubmed-article:16923518 | lifeskim:mentions | umls-concept:C0524910 | lld:lifeskim |
| pubmed-article:16923518 | lifeskim:mentions | umls-concept:C0332281 | lld:lifeskim |
| pubmed-article:16923518 | lifeskim:mentions | umls-concept:C1413036 | lld:lifeskim |
| pubmed-article:16923518 | lifeskim:mentions | umls-concept:C1999216 | lld:lifeskim |
| pubmed-article:16923518 | pubmed:issue | 8 Suppl | lld:pubmed |
| pubmed-article:16923518 | pubmed:dateCreated | 2006-8-22 | lld:pubmed |
| pubmed-article:16923518 | pubmed:abstractText | A deficiency of ADAMTS13 leads to platelet clumping and/or thrombi formation, finally resulting in thrombotic thrombocytopenic purpura (TTP). In this study, a 62-year-old male with chronic hepatitis C developed TTP a month after long-term pegylated-interferon (PEG-IFN) treatment. The observed low level of activity of plasma ADAMTS13 following PEG-IFN treatment was shown to gradually increase with the improvement of TTP, while the titer of an inhibitory anti- ADAMTS13 IgG antibody decreased concomitant with the increase in ADAMTS13 activity. Serial determination of ADAMTS13 activity and its inhibitor may provide useful information for the diagnosis and treatment of IFN-associated TTP, as well as its pathogenesis. | lld:pubmed |
| pubmed-article:16923518 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16923518 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16923518 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16923518 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16923518 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16923518 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16923518 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16923518 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16923518 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16923518 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16923518 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16923518 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:16923518 | pubmed:issn | 1592-8721 | lld:pubmed |
| pubmed-article:16923518 | pubmed:author | pubmed-author:MatsumotoMasa... | lld:pubmed |
| pubmed-article:16923518 | pubmed:author | pubmed-author:FujimuraYoshi... | lld:pubmed |
| pubmed-article:16923518 | pubmed:author | pubmed-author:IshidaFumihir... | lld:pubmed |
| pubmed-article:16923518 | pubmed:author | pubmed-author:KitanoKiyoshi... | lld:pubmed |
| pubmed-article:16923518 | pubmed:author | pubmed-author:KamijoAtsushi... | lld:pubmed |
| pubmed-article:16923518 | pubmed:author | pubmed-author:UemuraMasahit... | lld:pubmed |
| pubmed-article:16923518 | pubmed:author | pubmed-author:FurutaKiyoshi... | lld:pubmed |
| pubmed-article:16923518 | pubmed:author | pubmed-author:GiboYukioY | lld:pubmed |
| pubmed-article:16923518 | pubmed:author | pubmed-author:OguchiSatohir... | lld:pubmed |
| pubmed-article:16923518 | pubmed:author | pubmed-author:JoshitaSatoru... | lld:pubmed |
| pubmed-article:16923518 | pubmed:author | pubmed-author:TakahashiYasu... | lld:pubmed |
| pubmed-article:16923518 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:16923518 | pubmed:volume | 91 | lld:pubmed |
| pubmed-article:16923518 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16923518 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16923518 | pubmed:pagination | ECR34 | lld:pubmed |
| pubmed-article:16923518 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:16923518 | pubmed:meshHeading | pubmed-meshheading:16923518... | lld:pubmed |
| pubmed-article:16923518 | pubmed:meshHeading | pubmed-meshheading:16923518... | lld:pubmed |
| pubmed-article:16923518 | pubmed:meshHeading | pubmed-meshheading:16923518... | lld:pubmed |
| pubmed-article:16923518 | pubmed:meshHeading | pubmed-meshheading:16923518... | lld:pubmed |
| pubmed-article:16923518 | pubmed:meshHeading | pubmed-meshheading:16923518... | lld:pubmed |
| pubmed-article:16923518 | pubmed:meshHeading | pubmed-meshheading:16923518... | lld:pubmed |
| pubmed-article:16923518 | pubmed:meshHeading | pubmed-meshheading:16923518... | lld:pubmed |
| pubmed-article:16923518 | pubmed:meshHeading | pubmed-meshheading:16923518... | lld:pubmed |
| pubmed-article:16923518 | pubmed:meshHeading | pubmed-meshheading:16923518... | lld:pubmed |
| pubmed-article:16923518 | pubmed:meshHeading | pubmed-meshheading:16923518... | lld:pubmed |
| pubmed-article:16923518 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16923518 | pubmed:articleTitle | Thrombotic thrombocytopenic purpura associated with pegylated-interferon alpha-2a by an ADAMTS13 inhibitor in a patient with chronic hepatitis C. | lld:pubmed |
| pubmed-article:16923518 | pubmed:affiliation | Department of Internal Medicine, Matsumoto National Hospital,Matsumoto, Japan. kiyoshikitano@mac.com | lld:pubmed |
| pubmed-article:16923518 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16923518 | pubmed:publicationType | Case Reports | lld:pubmed |
| pubmed-article:16923518 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16923518 | lld:pubmed |
